Frequency, private specificity, and cross-reactivity of preexisting hepatitis C virus (HCV)-specific CD8+ T cells in HCV-seronegative individuals: Implications for vaccine responses

Journal of Virology

Volumn 89, Issue 16, 2015, Pages 8304-8317

  Zhang, Shihong ^a,b   Bakshi, Rakesh K ^a,b,e   Suneetha, Pothakamuri Venkata ^a   Fytili, Paraskevi ^a   Antunes, Dinler A ^c   Vieira, Gustavo F ^c   Jacobs, Roland ^a   Klade, Christoph S ^d   Manns, Michael P ^a   Kraft, Anke R M ^a   Wedemeyer, Heiner ^a   Schlaphoff, Verena ^a   Cornberg, Markus ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b Hannover Biomedical Research School   (Germany)

^c FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^d INTERCELL AG   (Austria)

^e University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; HEPATITIS C VACCINE; HEPATITIS C ANTIBODY; VIRUS VACCINE;

ANTIGEN RECOGNITION; ARTICLE; CD8+ T LYMPHOCYTE; CELL SPECIFICITY; CONTROLLED STUDY; CROSS REACTION; EX VIVO STUDY; EXPOSURE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO STUDY; INFECTION RISK; LYMPHOCYTE COUNT; MEMORY CELL; NONHUMAN; PRIORITY JOURNAL; RISK FACTOR; VIRUS INFECTION; COHORT ANALYSIS; HEPACIVIRUS; IMMUNOLOGY;

HEPATITIS C VIRUS;

CD8-POSITIVE T-LYMPHOCYTES; COHORT STUDIES; CROSS REACTIONS; HEPACIVIRUS; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMANS; VIRAL VACCINES;

EID: 84938152529     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00539-15     Document Type: Article

References (46)

1. Thimme R, Oldach D, Chang KM, Steiger C, Ray SC, Chisari FV. 2001. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 194:1395-1406. http://dx.doi.org/10.1084/jem.194.10.1395.
2. Lauer GM, Barnes E, Lucas M, Timm J, Ouchi K, Kim AY, Day CL, Robbins GK, Casson DR, Reiser M, Dusheiko G, Allen TM, Chung RT, Walker BD, Klenerman P. 2004. High-resolution analysis of cellular immune responses in resolved and persistent hepatitis C virus infection. Gastroenterology 127:924-936. http://dx.doi.org/10.1053/j.gastro.2004.06.015.
3. + T cells are required for protection from persistent hepatitis C virus infection. J Exp Med 197:1645-1655. http://dx.doi.org/10.1084/jem.20030239.
4. Swadling L, Capone S, Antrobus RD, Brown A, Richardson R, Newell EW, Halliday J, Kelly C, Bowen D, Fergusson J, Kurioka A, Ammendola V, Del Sorbo M, Grazioli F, Esposito ML, Siani L, Traboni C, Hill A, Colloca S, Davis M, Nicosia A, Cortese R, Folgori A, Klenerman P, Barnes E. 2014. A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCVspecific T cell memory. Sci Transl Med 6:261ra153. http://dx.doi.org/10.1126/scitranslmed.3009185.
5. + T cells. J Virol 88:11080-11090. http://dx.doi.org/10.1128/JVI.01590-14.
6. Fytili P, Dalekos GN, Schlaphoff V, Suneetha PV, Sarrazin C, Zauner W, Zachou K, Berg T, Manns MP, Klade CS, Cornberg M, Wedemeyer H. 2008. Cross-genotype-reactivity of the immunodominant HCV CD8 T-cell epitope NS3-1073. Vaccine 26:3818-3826. http://dx.doi.org/10.1016/j.vaccine.2008.05.045.
7. Kelly C, Swadling L, Brown A, Capone S, Folgori A, Salio M, Klenerman P, Barnes E. 2015. Cross-reactivity of hepatitis C virus specific vaccine-induced T cells at immunodominant epitopes. Eur J Immunol 45:309-316. http://dx.doi.org/10.1002/eji.201444686.
8. + T cell epitopes: implications for prevention and therapy of persistent hepatitis virus infections. Med Microbiol Immunol 204:29-38. http://dx.doi.org/10.1007/s00430-014-0372-z.
9. Kibuuka H, Berkowitz NM, Millard M, Enama ME, Tindikahwa A, Sekiziyivu AB, Costner P, Sitar S, Glover D, Hu Z, Joshi G, Stanley D, Kunchai M, Eller LA, Bailer RT, Koup RA, Nabel GJ, Mascola JR, Sullivan NJ, Graham BS, Roederer M, Michael NL, Robb ML, Ledgerwood JE, the RVST. 2014. Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, doubleblind, placebo-controlled clinical trial. Lancet 385:1545-1554. http://dx.doi.org/10.1016/S0140-6736(14)62385-0.
10. Kreijtz JH, Goeijenbier M, Moesker FM, van den Dries L, Goeijenbier S, De Gruyter HL, Lehmann MH, Mutsert G, van de Vijver DA, Volz A, Fouchier RA, van Gorp EC, Rimmelzwaan GF, Sutter G, Osterhaus AD. 2014. Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1/2a clinical trial. Lancet Infect Dis 14:1196-1207. http://dx.doi.org/10.1016/S1473-3099(14)70963-6.
11. Firbas C, Jilma B, Tauber E, Buerger V, Jelovcan S, Lingnau K, Buschle M, Frisch J, Klade CS. 2006. Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: a randomized, placebo controlled trial for dose optimization in 128 healthy subjects. Vaccine 24:4343-4353. http://dx.doi.org/10.1016/j.vaccine.2006.03.009.
12. Su LF, Davis MM. 2013. Antiviral memory phenotype T cells in unexposed adults. Immunological Rev 255:95-109. http://dx.doi.org/10.1111/imr.12095.
13. + T cells in unexposed blood donors. J Exp Med 211:1273-1280. http://dx.doi.org/10.1084/jem.20130555.
14. + memory-phenotype T cells are abundant in unexposed adults. Immunity 38:373-383. http://dx.doi.org/10.1016/j.immuni.2012.10.021.
15. Neveu B, Debeaupuis E, Echasserieau K, le Moullac-Vaidye B, Gassin M, Jegou L, Decalf J, Albert M, Ferry N, Gournay J, Houssaint E, Bonneville M, Saulquin X. 2008. Selection of high-avidity CD8 T cells correlates with control of hepatitis C virus infection. Hepatology 48:713-722. http://dx.doi.org/10.1002/hep.22379.
16. + T cells in hepatitis C virusexposed healthy seronegative donors. J Immunol 162:6681-6689.
17. Koziel MJ, Wong DK, Dudley D, Houghton M, Walker BD. 1997. Hepatitis C virus-specific cytolytic T lymphocyte and T helper cell responses in seronegative persons. J Infect Dis 176:859-866. http://dx.doi.org/10.1086/516546.
18. Meyer MF, Lehmann M, Cornberg M, Wiegand J, Manns MP, Klade C, Wedemeyer H. 2007. Clearance of low levels of HCV viremia in the ab-sence of a strong adaptive immune response. Virol J 4:58. http://dx.doi.org/10.1186/1743-422X-4-58.
19. + T cell responses is linked to naive-precursor frequency. J Virol 85:5232-5236. http://dx.doi.org/10.1128/JVI.00093-11.
20. Jenkins MK, Moon JJ. 2012. The role of naive T cell precursor frequency and recruitment in dictating immune response magnitude. J Immunol 188:4135-4140. http://dx.doi.org/10.4049/jimmunol.1102661.
21. + T-cell cross-reactivity and heterologous immunity. Immunol Rev 211:164-181. http://dx.doi.org/10.1111/j.0105-2896.2006.00394.x.
22. Wedemeyer H, Mizukoshi E, Davis AR, Bennink JR, Rehermann B. 2001. Cross-reactivity between hepatitis C virus and Influenza A virus determinant-specific cytotoxic T cells. J Virol 75:11392-11400. http://dx.doi.org/10.1128/JVI.75.23.11392-11400.2001.
23. Urbani S, Amadei B, Fisicaro P, Pilli M, Missale G, Bertoletti A, Ferrari C. 2005. Heterologous T cell immunity in severe hepatitis C virus infection. J Exp Med 201:675-680. http://dx.doi.org/10.1084/jem.20041058.
24. Welsh RM. 2006. Private specificities of heterologous immunity. Curr Opin Immunol 18:331-337. http://dx.doi.org/10.1016/j.coi.2006.03.002.
25. Kim SK, Cornberg M, Wang XZ, Chen HD, Selin LK, Welsh RM. 2005. Private specificities of CD8 T cell responses control patterns of heterologous immunity. J Exp Med 201:523-533. http://dx.doi.org/10.1084/jem.20041337.
26. Firbas C, Boehm T, Buerger V, Schuller E, Sabarth N, Jilma B, Klade CS. 2010. Immunogenicity and safety of different injection routes and schedules of IC41, a hepatitis C virus (HCV) peptide vaccine. Vaccine 28:2397-2407. http://dx.doi.org/10.1016/j.vaccine.2009.12.072.
27. Sinigaglia M, Antunes DA, Rigo MM, Chies JA, Vieira GF. 2013. CrossTope: a curate repository of 3D structures of immunogenic peptide: MHC complexes. Database (Oxford) 2013:bat002. http://dx.doi.org/10.1093/database/bat002.
28. Antunes DA, Rigo MM, Silva JP, Cibulski SP, Sinigaglia M, Chies JA, Vieira GF. 2011. Structural in silico analysis of cross-genotype reactivity among naturally occurring HCV NS3-1073-variants in the context of HLA-A*02:01 allele. Mol Immunol 48:1461-1467. http://dx.doi.org/10.1016/j.molimm.2011.03.019.
29. Quigley MF, Almeida JR, Price DA, Douek DC. 2011. Unbiased molecular analysis of T cell receptor expression using template-switch anchored RT-PCR. Curr Protoc Immunol Chapter 10:Unit10.33. http://dx.doi.org/10.1002/0471142735.im1033s94.
30. + T cells reveals conserved precursor frequencies. Blood 115:3718-3725. http://dx.doi.org/10.1182/blood-2009-10-251124.
31. + T cell cross-reactivity in individuals infected with hepatitis C virus. J Clin Invest 118:1143-1153. http://dx.doi.org/10.1172/JCI33082.
32. Zeremski M, Shu MA, Brown Q, Wu Y, Des Jarlais DC, Busch MP, Talal AH, Edlin BR. 2009. Hepatitis C virus-specific T-cell immune responses in seronegative injection drug users. J Viral Hepat 16:10-20. http://dx.doi.org/10.1111/j.1365-2893.2008.01016.x.
33. + T cells favor rapid memory differentiation and preservation of proliferative potential upon boosting. Immunity 39:171-183. http://dx.doi.org/10.1016/j.immuni.2013.07.003.
34. Wolchinsky R, Hod-Marco M, Oved K, Shen-Orr SS, Bendall SC, Nolan GP, Reiter Y. 2014. Antigen-dependent integration of opposing proximal TCR-signaling cascades determines the functional fate of T lymphocytes. J Immunol 192:2109-2119. http://dx.doi.org/10.4049/jimmunol.1301142.
35. Guy CS, Vignali KM, Temirov J, Bettini ML, Overacre AE, Smeltzer M, Zhang H, Huppa JB, Tsai YH, Lobry C, Xie J, Dempsey PJ, Crawford HC, Aifantis I, Davis MM, Vignali DA. 2013. Distinct TCR signaling pathways drive proliferation and cytokine production in T cells. Nat Immunol 14:262-270. http://dx.doi.org/10.1038/ni.2538.
36. Welsh RM, Fujinami RS. 2007. Pathogenic epitopes, heterologous immunity and vaccine design. Nat Rev Microbiol 5:555-563. http://dx.doi.org/10.1038/nrmicro1709.
37. + T cells to antigen stimulation in vivo. Nat Immunol 1:47-53. http://dx.doi.org/10.1038/76907.
38. Welsh RM, Selin LK. 2002. No one is naive: the significance of heterologous T-cell immunity. Nat Rev Immunol 2:417-426.
39. Birnbaum ME, Mendoza JL, Sethi DK, Dong S, Glanville J, Dobbins J, Ozkan E, Davis MM, Wucherpfennig KW, Garcia KC. 2014. Deconstructing the peptide-MHC specificity of T cell recognition. Cell 157: 1073-1087. http://dx.doi.org/10.1016/j.cell.2014.03.047.
40. Cornberg M, Chen AT, Wilkinson LA, Brehm MA, Kim SK, Calcagno C, Ghersi D, Puzone R, Celada F, Welsh RM, Selin LK. 2006. Narrowed TCR repertoire and viral escape as a consequence of heterologous immunity. J Clin Invest 116:1443-1456. http://dx.doi.org/10.1172/JCI27804.
41. Cornberg M, Clute SC, Watkin LB, Saccoccio FM, Kim SK, Naumov YN, Brehm MA, Aslan N, Welsh RM, Selin LK. 2010. CD8 T cell cross-reactivity networks mediate heterologous immunity in human EBV and murine vaccinia virus infections. J Immunol 184:2825-2838. http://dx.doi.org/10.4049/jimmunol.0902168.
42. + T cells recognizing mutant viral epitopes depends on peptide-MHC-I structural interactions and T cell activation threshold. PLoS Pathog 6:e1001039. http://dx.doi.org/10.1371/journal.ppat.1001039.
43. Brodin P, Jojic V, Gao T, Bhattacharya S, Angel CJ, Furman D, Shen-Orr S, Dekker CL, Swan GE, Butte AJ, Maecker HT, Davis MM. 2015. Variation in the human immune system is largely driven by nonheritable influences. Cell 160:37-47. http://dx.doi.org/10.1016/j.cell.2014.12.020.
44. Wolfl M, Rutebemberwa A, Mosbruger T, Mao Q, Li HM, Netski D, Ray SC, Pardoll D, Sidney J, Sette A, Allen T, Kuntzen T, Kavanagh DG, Kuball J, Greenberg PD, Cox AL. 2008. Hepatitis C virus immune escape via exploitation of a hole in the T cell repertoire. J Immunol 181:6435-6446. http://dx.doi.org/10.4049/jimmunol.181.9.6435.
45. Burke KP, Munshaw S, Osburn WO, Levine J, Liu L, Sidney J, Sette A, Ray SC, Cox AL. 2012. Immunogenicity and cross-reactivity of a representative ancestral sequence in hepatitis C virus infection. J Immunol 188:5177-5188. http://dx.doi.org/10.4049/jimmunol.1103008.
46. Honegger JR, Zhou Y, Walker CM. 2014. Will there be a vaccine to prevent HCV infection? Semin Liver Dis 34:79-88. http://dx.doi.org/10.1055/s-0034-1371081.